<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04728113</url>
  </required_header>
  <id_info>
    <org_study_id>IC 2019-09 EARLY TOGETHER</org_study_id>
    <nct_id>NCT04728113</nct_id>
  </id_info>
  <brief_title>Early Integration of Supportive Care for Metastatic Uveal Melanoma Patients (EarlyTogether)</brief_title>
  <official_title>Early Integration of Supportive Care Into Standard Oncology Care for Metastatic Uveal Melanoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Curie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study main objective is to assess whether the early introduction of supportive care&#xD;
      demonstrates a benefit on patients' psychological care needs at 6 months (M6), versus&#xD;
      oncological standard of care in patients with metastatic UM.&#xD;
&#xD;
      Supportive care in patients with metastatic Uveal Melanoma (UM)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the start of the study, medical oncologists and supportive care physicians from both&#xD;
      the sites will attend Communication Skills Training (CST) workshops provided by an expert&#xD;
      team in the field. The training sessions will focus on practicing the required communication&#xD;
      skills needed in consultations.&#xD;
&#xD;
      The randomization will assign patients, with a 1:2 ratio, to &quot;Introduction of supportive care&#xD;
      when medically needed&quot; (Arm A: Control Group) or &quot;Initial concomitant management by the&#xD;
      oncologist and the supportive care team&quot; (Arm B: Early Together Group).&#xD;
&#xD;
      Selected and validated questionnaires will be filled at baseline, 6 and 12 months by the&#xD;
      patients before the consultation, in the 2 groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2020</start_date>
  <completion_date type="Anticipated">July 16, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 16, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>34 items - Supportive Care Needs Survey</measure>
    <time_frame>6 months</time_frame>
    <description>The main study criterion is the score to the &quot;Care and Support Needs&quot; domain (items 18-22) of the SCNS-SF34 questionnaire obtained in the two arms at 6 months after inclusion. A 10 points mean score difference expected between groups. Each question is ranged from 0 (no need of supportive care) to 5 (strong need of supportive care). Scores for Outcome 1 may vary from 0 to 25.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Uveal Melanoma</condition>
  <arm_group>
    <arm_group_label>Early together group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oncological standard of care at M0, M3, M6, M9 and M12 with early introduction of supportive care every 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oncological standard of care at M0, M3, M6, M9 and M12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supportive care visit with questionnaires</intervention_name>
    <description>5 Questionnaires (SCNS, QLQ-C30, HADS, PTPQ, GSE) will be filled by the patient with introduction of supportive care visit</description>
    <arm_group_label>Early together group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oncological standard visit</intervention_name>
    <description>Oncological standard visit</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Early together group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. adult patients with metastatic UM;&#xD;
&#xD;
          2. no surgery or loco-regional treatment of metastases in a curative intent;&#xD;
&#xD;
          3. systemic treatment planned or started since less than 2 months;&#xD;
&#xD;
          4. ECOG PS 0-1;&#xD;
&#xD;
          5. no uncontrolled symptoms;&#xD;
&#xD;
          6. liver function tests in normal range or â‰¤ grade 2;&#xD;
&#xD;
          7. signed informed consent;&#xD;
&#xD;
          8. able to fill the questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. patient&lt;18 years old;&#xD;
&#xD;
          2. patient condition requiring supportive care before any systemic specific treatment for&#xD;
             metastases;&#xD;
&#xD;
          3. acute psychopathological disorder incompatible with the study;&#xD;
&#xD;
          4. prior medical condition incompatible with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PIPERNO NEUMAN Sophie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Curie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SANDRA NESPOULOUS</last_name>
    <phone>1 47 11 16 54</phone>
    <phone_ext>33</phone_ext>
    <email>sandra.nespoulous@curie.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauris GASTAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lauris GASTAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie PIPERNO NEUMANN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie PIPERNO NEUMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2021</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

